

SCOHIA initiates a Phase 1 study of a GPR40 full agonist (SCO-267)

SCOHIA PHARMA, Inc. today announced that a GPR40 full agonist (SCO-267) has progressed into a phase 1 study in healthy adults and people with impaired glucose tolerance.

This is a randomized, single-center, double-blind, placebo-controlled study, conducted in Japan, to evaluate the safety, tolerability, and pharmacokinetics of single as well as repeated oral doses of SCO-267 in Japanese and Caucasian healthy adults and Japanese people with impaired glucose tolerance, approximately 100 in total.

For more information about the study, visit the following website. <u>https://www.clinicaltrials.jp/cti-user/trial/Search.jsp</u> (Please search by JapicCTI-195057).

[About GPR40 full agonist (SCO-267)]

SCO-267 is one of the in-licensed compounds from Takeda Pharmaceutical Company Limited, and is a full agonist of G-protein-coupled receptor GPR40. GPR40, which is also a fatty acid receptor, is expressed in the islets and the gastrointestinal tract. Upon activation by SCO-267, it stimulates the secretion of hormones, mainly insulin in the pancreas and incretin in the gastrointestinal tract. This results in a significant reduction in blood glucose and loss of body weight. Consequently, this compound is expected to be a first-in-class oral drug for treating type 2 diabetes mellitus and obesity. Our company has presented <u>a paper on preclinical study</u> of SCO-267 and gave <u>an academic poster presentation on SCO-267</u> in preclinical animal <u>models</u>.



[About SCOHIA PHARMA, Inc.]

SCOHIA PHARMA, Inc. is a drug discovery bioventure focusing on the field of lifestylerelated diseases such as cardiovascular, metabolic, and renal diseases. Our R&D team has a rich pipeline and track record in each stage of drug development, including compound discovery, drug evaluation, and clinical development, which makes us special. For detailed information about SCOHIA PHARMA, Inc., please visit <u>https://www.scohia.com/eng/</u>.